TYKERB

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Hong Kong SAR China, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, Turkey.

Active ingredients

The drug TYKERB contains one active pharmaceutical ingredient (API):

1	Lapatinib UNII G873GX646R - LAPATINIB DITOSYLATE
	Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and of HER2 (ErbB2) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a slow off-rate from these receptors (half-life greater than or equal to 300 minutes). Lapatinib inhibits ErbB-driven tumour cell growth in vitro and in various animal models.
	Read more about Lapatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TYKERB Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EH01	Lapatinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
Discover more medicines within L01EH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11251E, 9148L
BR	Câmara de Regulação do Mercado de Medicamentos	526517060090017
CA	Health Products and Food Branch	02326442
HK	Department of Health Drug Office	56194
IL	מִשְׂרַד הַבְּרִיאוּת	6192
JP	医薬品医療機器総合機構	4291022F1026
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	417M2008
NZ	Medicines and Medical Devices Safety Authority	13000
SG	Health Sciences Authority	13366P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504092127
US	FDA, National Drug Code	0078-0671
ZA	Health Products Regulatory Authority	42/26/0275